Myocardial infarction risk and the clinical significance of metabolic syndrome in the absence of hypertension and diabetes: Insights from a large cohort screening population
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.12.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Soroush Masrouri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Prevention of Metabolic Disorders Research Center, Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences,…. Hauptthemen laut MEDLINE: Metabolic Syndrome, Myocardial Infarction, Hypertension, Diabetes Mellitus. Die Arbeit nennt 63 Literaturangaben. Gefördert von: Amgen, Boehringer Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: To examine associations between metabolic syndrome (MetS), its components, and MetS subgroups based on the absence or presence of hypertension (HTN) and diabetes mellitus (DM), with incident myocardial infarction (MI). METHODS: Among 7824 Tehran Lipid and Glucose Study participants (mean age 46.9 years; 44.9% men) without baseline cardiovascular disease, multivariable Cox models and restricted cubic spline analyses assessed the associations of MetS, its subgroups, and components with incident MI. RESULTS: Of the 7824 participants included, 4092 (52.3%) were free of MetS. Among participants with MetS, 1847 (49.5%) had neither DM nor HTN, 1217 (32.6%) had HTN only (DM-/HTN+), 330 (8.8%) had DM only (DM+/HTN-), and 338 (9.1%) had both DM and HTN (DM+/HTN+). During a median follow-up of 19.9 years, 252 MI events occurred. Compared with MetS-free individuals, the adjusted hazard ratio (HR) of MetS for incident MI was 2.04 (95% CI: 1.54-2.70). HRs were 1.41 (1.00-1.99) for MetS (DM-/HTN-), 2.06 (1.44-2.95) for MetS (DM-/HTN+), 3.40 (2.15-5.38) for MetS (DM+/HTN-), and 5.09 (3.33-7.81) for MetS (DM+/HTN+) subgroups. Individuals with MetS but without the elevated glucose component or HTN were still at increased risk of MI. Using the American College of Cardiology/American Heart Association definition of HTN did not alter the findings. All MetS components showed significant associations with MI. After adjustment for the other MetS components, elevated waist circumference (HR: 1.47, 95% CI: 1.09-1.98) and elevated blood pressure (1.50; 1.14-1.98) components were associated with higher risk of MI. CONCLUSION: MetS in the absence of HTN and DM conferred a greater risk of MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Prevention of Metabolic Disorders Research Center, Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Drs Mas…
- Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA (Dr Shapiro).
- Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Dr Azizi).
Förderung
- Amgen
- Boehringer Ingelheim
Zitieren
APA
Masrouri, S., Ebrahimi, N., Zooravar, D., Shapiro, M. D., Azizi, F., & Hadaegh, F. (2025). Myocardial infarction risk and the clinical significance of metabolic syndrome in the absence of hypertension and diabetes: Insights from a large cohort screening population. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.12.006
Vancouver
Masrouri S, Ebrahimi N, Zooravar D, Shapiro MD, Azizi F, Hadaegh F. Myocardial infarction risk and the clinical significance of metabolic syndrome in the absence of hypertension and diabetes: Insights from a large cohort screening population. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.12.006
BibTeX
@article{Masrouri2025,
author = {Masrouri, Soroush and Ebrahimi, Navid and Zooravar, Diar and Shapiro, Michael D and Azizi, Fereidoun and Hadaegh, Farzad},
title = {Myocardial infarction risk and the clinical significance of metabolic syndrome in the absence of hypertension and diabetes: Insights from a large cohort screening population},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.12.006}
}
EUVIMED